We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Polyplus-transfection Licenses Kempbio for Mammalian Transient Transfection Technology
News

Polyplus-transfection Licenses Kempbio for Mammalian Transient Transfection Technology

Polyplus-transfection Licenses Kempbio for Mammalian Transient Transfection Technology
News

Polyplus-transfection Licenses Kempbio for Mammalian Transient Transfection Technology

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Polyplus-transfection Licenses Kempbio for Mammalian Transient Transfection Technology"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Polyplus-transfection SA has announced that Kempbio, Inc., a provider of high quality bioservices to the biotechnology and biopharmaceutical industry, has signed a license agreement to use polyethylenimine (PEI) for the transfection of cells used for the production of recombinant proteins.

By signing this license, Kempbio becomes one of Polyplus’ sub-licensees for the use of PEI technology for the expression of proteins on milligram and gram scales using the human cell line HEK-293 and other mammalian host cells.

The production of recombinant proteins in human cell lines results in authentic human post-translational processing providing advantages for the stability and biological activity of proteins useful in the development of human therapeutics and diagnostic reagents.

“We are truly delighted to sign this license agreement with Kempbio, a company offering quality cell culture and protein expression services,” said Mark Bloomfield, CEO of Polyplus-transfection. “PEI is clearly the reagent of choice for research into large-scale mammalian transient transfection, and this agreement allows Kempbio to use PEI for its transfection services offering. Our business relationship with Kembio also demonstrates the significant value of our intellectual property rights in the field of PEI-mediated nucleic acid delivery.”

Financial terms were not disclosed.
Advertisement